FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/09/2025
Voltar para busca
Dado oficial do USPTO
MYOSCREEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
MYOSCREEN
ST13
US500000079382428Classe
5, 9, 42
Pedido
79382428
Registro
7691258
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 42
Data de depósito
26/05/2023
Data de registro
18/02/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/02/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
FR
Examinador
REID, CAILE MAUREEN
Unidade examinadora
N50
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
CYTOO
Representantes
Steven J. Solomon Tucker Ellis LLP
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical productsnamely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseases; veterinary productsnamely veterinary preparations for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseases; sanitary preparations for medical use; chemical and biological preparations for medical usenamely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseases; chemical and biological preparations for pharmaceutical use for the prevention and the treatment of muscle dysfunction associated diseasesmuscle dystrophiesmuscle metabolic diseasesmuscle atrophy associated diseasessarcopeniacancercachexiaobesitydiabetes and cardiovascular diseasesrenal diseasesnephropathiesneuropathiesretinopathiesneurodegenerativepsychiatric and cognitive diseasesmetabolic diseasesinflammatory diseasesbiological preparations for pharmaceutical use being biological preparations for use in cell cultures for medical purposes
Classe 9
Quality control and testing devices namely culture plates to test and conduct quality control in the field of biologybiotechnology and pharmacy; downloadable software for the collectionprocessing and analysis of data in the field of biotechnology and pharmacy; scientific laboratory instrumentsnamely computer hardware and downloadable software for data analysisdatabase managementdata processingin the field of life science research and the pharmaceutical industry market and diagnostics
Classe 42
Medicalbiotechnologicalpharmaceutical research; research and development of chemicalbiological and scientific products and materials in the biologicalbiotechnologicalmedicaldiagnostic and pharmaceutical fields; scientific researchadvisory and information services in the medicalbiotechnologicalpharmaceuticaldiagnostictechnological and industrial fields; design and development of computerssoftware and computer platforms; technical testing namely technological testing in the scientificbiologicalbiotechnological and medical fields and quality control services of goods and services; advisory services with respect to quality testingtechnical testing namelytechnological testing in the scientificbiologicalbiotechnological and medical fieldsscientific research advisory services with respect to scientific and medical clinical trials; services for scientific development and analysis of cell tests; scientific and medical research and development of products and services in the field of imagingin the scientificbiologicalbiochemicalmolecular-biologybiotechnological and medical fields; Scientific interpretation and analysis of data by imaging in the scientificbiologicalbiochemicalmolecular-biologybiotechnological and medical fields; diagnostic and industrial research in the biologicalbiotechnological and medical fields
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
31/08/2025
FIMP
FINAL DISPOSITION PROCESSED
31/08/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
18/05/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
19/04/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
31/03/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
31/03/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
18/02/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
18/02/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/12/2024
PUBO
PUBLISHED FOR OPPOSITION
31/12/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
25/12/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/10/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
22/10/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
22/10/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
22/10/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
22/10/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/09/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/09/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/09/2024
RFNT
REFUSAL PROCESSED BY IB
16/04/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/03/2024
RFRR
REFUSAL PROCESSED BY MPU
25/03/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/03/2024
CNRT
NON-FINAL ACTION WRITTEN
01/03/2024
DOCK
ASSIGNED TO EXAMINER
20/02/2024
MAFR
APPLICATION FILING RECEIPT MAILED
07/11/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/11/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/11/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MYOSCREEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.